Skip to main navigation
  • Investors
  • Careers
  • Contact
Veradermics, Inc. corp site
  • About Us
  • VDPHL01
  • About PHL
  • Clinical Trials
  • About Us
  • VDPHL01
  • About PHL
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financial Information
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Information Request
  • Careers
  • Contact

Event Details

  • Overview
  • News & Events
  • Stock
  • Corporate Governance
  • Financial Information
  • Shareholder Services
  • News Releases
  • Events
  • Presentations

Study 302 Phase 2/3 Topline Results

Apr 27, 2026 8:00 AM EDT

Click here for webcast

Supporting Materials

Study 302 Phase 2/3 Topline Results Presentation 5.9 MB
Veradermics, Inc. footer logo

470 James St., Suite 2
New Haven, CT 06513

 

+1.22.VERA.DERM
(+1.228.372.3376)

twitter twitter twitter
  • Home
  • About Us
  • VDPHL01
  • About PHL
  • Clinical Trials
  • Investors
  • Careers
  • Contact
Our mission

To set a new standard  in pattern hair loss by developing treatments rooted in real evidence.

MANE NYSE Logo

© 2026 Veradermics, Inc. All Rights Reserved.

  • Terms of Use
  • Privacy Policy
  • Washington State Privacy